The following non-invasive assessments for advanced fibrosis are available for patients with NAFLD: clinical decision support tools (such as the NAFLD fibrosis score, FIB-4I, AST to platelet ratio index [APRI], BMI, AST to ALT ratio, DM index [BARD], and AST to ALT ratio); serum biomarkers (e.g., Enhanced Liver Fibrosis panel, Fibrometer, FibroTest, and Hepascore); and imaging techniques (including transient elastography and magnetic resonance imaging) [9]. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.